CGTX
NASD Cognition Therapeutics, Inc.$0.7345 ↑ +0.0019 (+0.26%) Trading Up from the previous close of $0.7326, $0.0529 below the day’s high of $0.7874
- YTD change
- -45.59%
- vs 20-day SMA
- -19.65%
- vs 200-day SMA
- -33.52%
Price ranges
Price & Performance
-0.38 (-34.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 94.7% away from all-time highs of $13.8000
- CGTX is down 46% since the beginning of the year
- CGTX is down 60% over the past 12 months
- CGTX is down 31% over the past 1 month
- 9% of all CGTX investors are betting against CGTX
CGTX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -60.4%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0044
- Last 5 days
- -17.95%
- vs 8-day SMA
- -13.80%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
